Michael R. Green, PHD

Peer-Reviewed Articles

1. Cui, G, Ley, M, Mechaly, A, Bui, LC, Michail, C, Berthelet, J, Dairou, J, Yang, H, Chevreux, G, Moroy, G, Green, M, Haouz, A, Rodrigues-Lima, F. Structural and functional characterization of CREB-binding protein (CREBBP) as a histone propionyltransferase. Journal of Biological Chemistry 301(8), 2025. e-Pub 2025. PMID: 40615044.
2. Li X, Singhal K, Deng Q, Chihara D, Russler-Germain D, Harkins RA, Henderson J, Arita K, Kizhakeyil A, Sun R, Lakra P, Hussein U, Foltz JA, Wilson A, Schmidt E, Nizamuddin I, Dinh T, Kesaraju A, Hamilton MP, Allen C, Gandhi MK, Tobin J, Jiang A, Hilton L, Scott DW, Vega F, Flowers CR, Westin JR, Griffith OL, Fehniger TA, Griffith M, Green MR. Large B cell lymphoma microenvironment archetype profiles. Cancer Cell 43(7):1347-1364, 2025. e-Pub 2025. PMID: 40920660.
3. Haopeng Y, Zhang W, Ravanmehr V, Cui G, Bowman K, Chen R, Henderson JM, Lockman S, Rojas E, Wilson A, Parsons S, Mechaly A, Regad L, Hauz A, Flowers CR, Neelapu S, Nastoupil L, Davis R, Deng Q, Rodrigues-Lima F, Green MR. Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement. Blood 146(2):191-205, 2025. e-Pub 2025. PMID: 40090010.
4. Lone, W, Bouska, A, Herek, TA, Amador, C, Song, JY, Xu, AM, Jochum, D, Issa, II, Weisenburger, DD, Zhang, X, Bhagavathi, S, Heavican-Foral, TB, Sharma, S, Shah, AR, Mir, AR, Alkhinji, AA, El-Gamal, D, Dave, BJ, Hartert, K, Yu, J, Saumyaranjan, M, Greiner, TC, Vose, J, McKeithan, TW, Fu, K, Green, M, Bi, C, Merchant, AA, Chan, WC, Iqbal, J. High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures. American journal of hematology 100(1):10-22, 2025. e-Pub 2025. PMID: 39548807.
5. Wang, B, Reville, PK, Yassouf, MY, Jelloul, FZ, Ly, C, Desai, PN, Wang, Z, Borges, P, Veletic, I, Dasdemir, E, Burks, JK, Tang, G, Guo, S, Garza, AI, Nasnas, C, Vaughn, NR, Baran, N, Deng, Q, Matthews, JA, Gunaratne, PH, Antunes, DA, Ekmekcioglu, S, Sasaki, K, Garcia, MB, Cuglievan, B, Hao, D, Daver, N, Green, M, Konopleva, M, Futreal, A, Post, SM, Abbas, HA. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38418901.
6. MacManus, M, Seymour, JF, Tsang, H, Fisher, R, Keane, C, Sabdia, MB, Law, SC, Gunawardana, J, Nath, K, Kazakoff, SH, Marques-Piubelli, ML, Duenas, DE, Green, M, Roos, D, O'Brien, PF, McCann, A, Tsang, R, Davis, S, Christie, D, Cheah, CY, Amanuel, B, Cochrane, T, Butler, J, Johnston, A, Shanavas, M, Li, L, Vajdic, CM, Kridel, R, Shelton, V, Hershenfield, S, Baetz, T, LeBrun, DP, Johnson, N, Brodtkorb, M, Ludvigsen, M, d'Amore, F, Thompson, E, Blombery, P, Gandhi, MK, Tobin, J. Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma. EBioMedicine 110, 2024. e-Pub 2024. PMID: 39631145.
7. Kumar, EA, Korfi, K, Bewicke-Copley, F, Close, K, Heward, J, Witzig, TE, Leukam, M, Ansell, SM, Scott, J, Clear, A, Efeyan, A, Green, M, Siebert, R, Peck, B, Calaminici, M, Wang, J, Smith, SM, Novak, AJ, Fitzgibbon, J, Okosun, J. CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma. British Journal of Haematology 205(5):1804-1809, 2024. e-Pub 2024. PMID: 39188028.
8. Gunawardana, J, Law, SC, Sabdia, MB, Fennell, É, Hennessy, A, Leahy, CI, Murray, P, Bednarska, K, Brosda, S, Trotman, J, Berkahn, L, Zaharia, A, Birch, S, Burgess, M, Talaulikar, D, Lee, JN, Jude, E, Hawkes, E, Jain, S, Nath, K, Snell, C, Swain, F, Tobin, J, Keane, C, Shanavas, M, Blyth, E, Steidl, C, Savage, KJ, Farinha, P, Boyle, M, Meissner, B, Green, M, Vega Vazquez, F, Gandhi, MK. Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma. American journal of hematology 99(11):2096-2107, 2024. e-Pub 2024. PMID: 39152767.
9. Sarrot R, Gourisankar S, Karim B, Nettles S, Yang H, Dwyer B, Simanauskaite J, Tse J, Abuzaid H, Krokhotin A, Zhang T, Hinshaw S, Green MR, Crabtree G, Gray N. Relocalizing transcriptional kinases to activate apoptosis. Science 386(6717), 2024. PMID: 39361741.
10. DiNardo, C, Verma, D, Baran, N, Bhagat, TD, Skwarska, A, Lodi, A, Saxena, K, Cai, T, Su, X, Guerra, VA, Poigaialwar, G, Kuruvilla, VM, Konoplev, S, Gordon-Mitchell, S, Pradhan, K, Alluri, S, Hackman, GL, Chaudhry, S, Collins, M, Sweeney, SR, Busquets, J, Rathore, AS, Deng, Q, Green, M, Grant, S, Demo, SD, Choudhary, GS, Sahu, S, Agarwal, B, Spodek, M, Thiruthuvanathan, V, Will, B, Steidl, U, Tippett, G, Burger, JA, Borthakur, G, Jabbour, EJ, Pemmaraju, N, Kadia, TM, Kornblau, SM, Daver, N, Naqvi, K, Short, NJ, Garcia-Manero, G, Tiziani, S, Verma, A, Konopleva, M. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes. Nature Cancer 5(10):1515-1533, 2024. e-Pub 2024. PMID: 39300320.
11. Plotnik J, Richardson A, Yang H, Rojas E, Bontcheva V, Dowell C, Parsons S, Wilson A, Ravanmehr V, Will C, Jung P, Zhu H, Partha S, Panchal S, Mali R, Kohlhapp F, McClure R, Ramathal C, George M, Jhala M, Elsen N, Qiu W, Judge R, Pan C, Mastracchio A, Henderson J, Meulbroek J, Green MR, Pappano W. Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma. Molecular Cancer Research 23(7):949-960, 2024. e-Pub 2024. PMID: 38507740.
12. Barisic D, Chin CR, Meydan C, Teater M, Tsialta I, Mlynarczyk C, Chadburn A, Wang X, Sarkozy M, Xia M, Carson SE, Raggiri S, Debek S, Pelzer B, Durmaz C, Deng Q, Lakra P, Rivas M, Steidl C, Scott DW, Weng AP, Mason CE, Green MR, Melnick A. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B-cell fate and lymphomagenesis. Cancer Cell 42(4):583-604.e11, 2024. e-Pub 2024. PMID: 38458187.
13. Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W, Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J, Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK, Allen C, Mason C, Melnick A, Green MR. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell 42(4):605-622.e11, 2024. e-Pub 2024. PMID: 38458188.
14. Gordon, MJ, Feng, L, Strati, P, Lee, HJ, Hagemeister, FB, Westin, JR, Samaniego, F, Marques-Piubelli, ML, Vega Vazquez, F, Parra Cuentas, ER, Solis Soto, LM, Ma, W, Wang, J, Claret, LC, Averill, B, Ibanez, K, Fayad, LE, Flowers, CR, Green, M, Davis, RE, Neelapu, SS, Fowler, N, Nastoupil, L. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma. Cancer 130(6):876-885, 2024. e-Pub 2024. PMID: 37985359.
15. Chu, F, Cao, J, Liu, J, Yang, H, Davis, TJ, Kuang, SQ, Cheng, X, Zhang, Z, Karri, S, Vien, LT, Bover, L, Sun, R, Vega Vazquez, F, Green, M, Davis, RE, Neelapu, SS. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas. Journal for immunotherapy of cancer 11(11), 2023. e-Pub 2023. PMID: 38007239.
16. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Padmanabhan Iyer S, Horowitz SB, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma. Blood Adv 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
17. Li, X, Henderson, J, Gordon, MJ, Sheikh, IN, Nastoupil, L, Westin, JR, Flowers, CR, Ahmed, S, Wang, L, Neelapu, SS, Strati, P, Deng, Q, Green, M. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer cell 41(11):1835-1837, 2023. e-Pub 2023. PMID: 37738975.
18. Strati, P, Li, X, Deng, Q, Marques-Piubelli, ML, Henderson, J, Watson, G, Deaton, FL, Cain, JT, Yang, H, Ravanmehr, V, Fayad, LE, Iyer, SP, Nastoupil, L, Hagemeister, FB, Parra, ER, Saini, N, Takahashi, K, Fowler, N, Westin, JR, Steiner, RE, Nair, R, Flowers, CR, Wang, L, Ahmed, S, Al-Atrash, G, Vega, F, Neelapu, SS, Green, M. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Reports Medicine 4(8):101158, 2023. e-Pub 2023. PMID: 37586321.
19. Gourisankar, S, Krokhotin, A, Ji, W, Liu, X, Chang, CY, Kim, SH, Li, Z, Wenderski, W, Simanauskaite, JM, Yang, H, Vogel, H, Zhang, T, Green, M, Gray, NS, Crabtree, GR. Rewiring cancer drivers to activate apoptosis. Nature 620(7973):417-425, 2023. e-Pub 2023. PMID: 37495688.
20. Desai, PN, Wang, B, Fonseca, A, Borges, P, Jelloul, FZ, Reville, PK, Lee, E, Ly, C, Basi, A, Root, J, Baran, N, Post, SM, Deng, Q, Sun, H, Harmanci, AO, Burks, JK, Gomez, JA, DiNardo, C, Daver, N, Al-Atrash, G, Konopleva, M, Green, M, Antunes, DA, Futreal, A, Hao, D, Abbas, HA. Single-Cell Profiling of CD8þ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunology Research 11(7):1011-1028, 2023. e-Pub 2023. PMID: 37163233.
21. Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, Manasanch EE. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41(6):1032-1047.e4, 2023. e-Pub 2023. PMID: 37311413.
22. Chu, Y, Dai, E, Li, Y, Han, G, Pei, G, Ingram, D, Thakkar, K, Qin, JJ, Dang, M, Le, X, Hu, C, Deng, Q, Sinjab, A, Gupta, P, Wang, R, Hao, D, Peng, F, Yan, X, Liu, Y, Song, S, Zhang, S, Heymach, JV, Reuben, A, Elamin, YY, Pizzi, MP, Lu, Y, Segura Lazcano, R, Hu, J, Li, M, Curran, M, Futreal, A, Maitra, A, Jazaeri, AA, Ajani, JA, Swanton, C, Cheng, XD, Abbas, HA, Gillison, M, Bhat, KP, Lazar, A, Green, M, Litchfield, K, Kadara, HN, Yee, C, Wang, L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nature medicine 29(6):1550-1562, 2023. e-Pub 2023. PMID: 37248301.
23. Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv 7(7):1137-1145, 2023. e-Pub 2023. PMID: 36375046.
24. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemeister FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. Exp Hematol Oncol 12(1):32, 2023. e-Pub 2023. PMID: 36941707.
25. Imahashi, N, Basar, R, Huang, Y, Wang, F, Baran, N, Banerjee, PP, Lu, J, Nunez Cortes, AK, Uprety, N, Ensley, E, Muniz-Feliciano, L, Laskowski, TJ, Moyes, JS, Daher, M, Mendt Vilchez, MC, Kerbauy, LN, Shanley, M, Li, L, Lim, FI, Shaim, H, Li, Y, Konopleva, M, Green, M, Wargo, J, Shpall, E, Chen, K, Rezvani, K. Activated B cells suppress T-cell function through metabolic competition. Journal for immunotherapy of cancer 10(12), 2022. e-Pub 2022. PMID: 36543374.
26. Fahrmann, JF, Saini, N, Chang, C, Irajizad, E, Strati, P, Nair, R, Fayad, LE, Ahmed, S, Lee, HJ, Iyer, SP, Steiner, RE, Vykoukal, JV, Wu, R, Dennison, JB, Nastoupil, L, Jain, P, Wang, L, Green, M, Westin, JR, Blumenberg, V, Davila, ML, Champlin, RE, Shpall, E, Kebriaei, P, Flowers, CR, Jain, MD, Jenq, RR, Thoeringer, C, Subklewe, M, Neelapu, SS, Hanash, S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Reports Medicine 3(11), 2022. e-Pub 2022. PMID: 36384092.
27. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
28. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. Journal of Clinical Oncology 41(4):745-755, 2022. e-Pub 2022. PMID: 35952327.
29. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad LE, Fowler NH, Parmar S, Steiner RE, Hagemeister FB, Nair R, Lee HJ, Rodriguez MA, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin JR. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
30. Han G, Deng Q, Marques-Piubelli M, Dai E, Dang M, Ma M, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie K, Bagaev A, Parra E, Soto L, Parmar S, Hagemeister F, Ahmed S, Iyer S, Samaniego F, Steiner R, Fayad L, Lee H, Fowler F, Flowers C, Strati P, Westin J, Neelapu S, Nastoupil L, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discovery 3(5):428-443, 2022. e-Pub 2022. PMID: 35687817.
31. Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, Moore D, Akhter A, Hartert K, Jain N, Showell J, Ghosh S, Street L, Davidson M, Carey C, Tobin J, Perumal D, Vose JM, Lunning MA, Sohani AR, Chen BJ, Buckley S, Nastoupil LJ, Davis RE, Westin JR, Fowler NH, Parekh S, Gandhi M, Neelapu S, Stewart D, Bhalla K, Iqbal J, Greiner T, Rodig SJ, Mansoor A, Green MR. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica 107(3):690-701, 2022. e-Pub 2022. PMID: 33792219.
32. Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv 6(4):1143-1151, 2022. e-Pub 2022. PMID: 35015819.
33. Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. Blood 139(6):907-921, 2022. e-Pub 2022. PMID: 34601571.
34. Jing Y, Liu Y, Li Q, Ye Y, Diao L, Huang Y, Zhou Y, Green MR, Mills GB, Han L. Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. Cancer Cell 39(12):1558-1559, 2021. e-Pub 2021. PMID: 34678153.
35. Szydlowski M, Garbicz F, Jablonska E, Górniak P, Komar D, Pyrzynska B, Bojarczuk K, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Rymkiewicz G, Cybulska M, Statkiewicz M, Gajewska M, Mikula M, Golas A, Domagala J, Winiarska M, Graczyk-Jarzynka A, Bialopiotrowicz E, Polak A, Barankiewicz J, Pula B, Pawlak M, Nowis D, Golab J, Tomirotti AM, Brzózka K, Pacheco-Blanco M, Kupcova K, Green MR, Havranek O, Chapuy B, Juszczynski P. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Res 81(23):6029-6043, 2021. e-Pub 2021. PMID: 34625423.
36. Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
37. Fiskus, WC, Mill, CP, Perera, D, Birdwell, C, Deng, Q, Yang, H, Lara, BH, Jain, N, Burger, JA, Ferrajoli, A, Davis, JA, Saenz, DT, Jin, W, Coarfa, C, Crews, CM, Green, M, Khoury, J, Bhalla, K. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia 35(9):2621-2634, 2021. e-Pub 2021. PMID: 33654205.
38. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
39. Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, Künkele A, Huisinga W, Strati P, Chasen B, Neelapu SS, Yee C, Kloft C. Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34205020.
40. Fiskus, WC, Mill, CP, Nabet, B, Perera, D, Birdwell, C, Manshouri, T, Lara, BH, Kadia, TM, DiNardo, C, Takahashi, K, Daver, N, Bose, P, Masarova, L, Pemmaraju, N, Kornblau, SM, Borthakur, G, Montalban Bravo, G, Garcia-Manero, G, Sharma, S, Stubbs, M, Su, X, Green, M, Coarfa, C, Verstovsek, S, Khoury, J, Vakoc, CR, Bhalla, K. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood cancer journal 11(5), 2021. e-Pub 2021. PMID: 34016956.
41. Veazey KJ, Cheng D, Lin K, Villarreal OD, Gao G, Perez-Oquendo M, Van HT, Stratton SA, Green M, Xu H, Lu Y, Bedford MT, Santos MA. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas. Leukemia 34(12):3269-3285, 2020. e-Pub 2020. PMID: 32576962.
42. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T-cell infusion products associated with efficacy and toxicity in patients with large B-cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
43. Swenson SA, Gilbreath TJ, Vahle H, Hynes-Smith RW, Graham JH, Law HC, Amador C, Woods NT, Green MR, Buckley SM. E3 Ligase, UBR5, HECT domain mutations in lymphoma control maturation of B cells. Blood 136(3):299-312, 2020. e-Pub 2020. PMID: 32325489.
44. Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, Béguelin W, Lee TC, Kim Y, Chin CR, Yewdell WT, Raught B, Phillip JM, Jiang Y, Staudt LM, Green MR, Chaudhuri J, Elemento O, Farinha P, Weng AP, Nissen MD, Steidl C, Morin RD, Scott DW, Privé GG, Melnick AM. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell 182(2):297-316.e27, 2020. e-Pub 2020. PMID: 32619424.
45. Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 4(13):3123-3127, 2020. e-Pub 2020. PMID: 32645136.
46. Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood 135(15):1255-1269, 2020. e-Pub 2020. PMID: 32068780.
47. Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MR. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov, 2020. e-Pub 2020. PMID: 31915197.
48. Parsa S, Ortega-Molina A, Ying HY, Jiang M, Teater M, Wang J, Zhao C, Reznik E, Pasion JP, Kuo D, Mohan P, Wang S, Camarillo JM, Thomas PM, Jain N, Garcia-Bermudez J, Cho BK, Tam W, Kelleher NL, Socci N, Dogan A, De Stanchina E, Ciriello G, Green MR, Li S, Birsoy K, Melnick AM, Wendel HG. The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. Nat Cancer 1:653-664, 2020. e-Pub 2020. PMID: 33569544.
49. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood 134(1):59-73, 2019. e-Pub 2019. PMID: 31023702.
50. Wang S, Mondal S, Zhao C, Berishaj M, Ghanakota P, Batlevi CL, Dogan A, Seshan VE, Abel R, Green MR, Younes A, Wendel HG. Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. JCI Insight 4(12), 2019. e-Pub 2019. PMID: 31217352.
51. Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci Transl Med 11(497), 2019. e-Pub 2019. PMID: 31217338.
52. Li M, Chiang YL, Lyssiotis CA, Teater MR, Hong JY, Shen H, Wang L, Hu J, Jing H, Chen Z, Jain N, Duy C, Mistry SJ, Cerchietti L, Cross JR, Cantley LC, Green MR, Lin H, Melnick AM. Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer Cell 35(6):916-931.e9, 2019. e-Pub 2019. PMID: 31185214.
53. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol 185(5):874-882, 2019. e-Pub 2019. PMID: 30919940.
54. Vicente-Dueñas C, González-Herrero I, Sehgal L, García-Ramírez I, Rodríguez-Hernández G, Pintado B, Blanco O, Criado FJG, Cenador MBG, Green MR, Sánchez-García I. Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia. Leukemia 33(1):249-278, 2019. e-Pub 2019. PMID: 29955131.
55. Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M, Mouly E, Torres-Martin M, Doane AS, Calvo Fernandez MT, Durant M, Della-Valle V, Teater M, Cimmino L, Droin N, Tadros S, Motanagh S, Shih AH, Rubin MA, Tam W, Aifantis I, Levine RL, Elemento O, Inghirami G, Green MR, Figueroa ME, Bernard OA, Aoufouchi S, Li S, Shaknovich R, Melnick AM. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer Discov 8(12):1632-1653, 2018. e-Pub 2018. PMID: 30274972.
56. Keane C, Tobin J, Talaulikar D, Green M, Crooks P, Jain S, Gandhi M. A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. Oncotarget 9(34):23620-23627, 2018. e-Pub 2018. PMID: 29805761.
57. Choi J, Lee K, Ingvarsdottir K, Bonasio R, Saraf A, Florens L, Washburn MP, Tadros S, Green MR, Busino L. Loss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor roquin2. Nat Cell Biol 20(May 2018):586-596, 2018. e-Pub 2018. PMID: 29695787.
58. Kunder CA, Roncador G, Advani RH, Gualco G, Bacchi CE, Sabile JM, Lossos IS, Nie K, Tibshirani RJ, Green MR, Alizadeh AA, Natkunam Y. KLHL6 is preferentially expressed In germinal center-derived B-cell lymphomas. Am J Clin Pathol 148(6):465-476, 2017. e-Pub 2017. PMID: 29140403.
59. García-Ramírez I, Tadros S, González-Herrero I, Martín-Lorenzo A, Rodríguez-Hernández G, Moore D, Ruiz-Roca L, Blanco O, Alonso-López D, Rivas JL, Hartert K, Duval R, Klinkebiel D, Bast M, Vose J, Lunning M, Fu K, Greiner T, Rodrigues-Lima F, Jiménez R, Criado FJG, Cenador MBG, Brindle P, Vicente-Dueñas C, Alizadeh A, Sánchez-García I, Green MR. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. Blood 129(19):2645-2656, 2017. e-Pub 2017. PMID: 28288979.
60. Keane C, Gould C, Jones K, Hamm D, Talaulikar D, Ellis J, Vari F, Birch S, Han E, Wood P, Le-Cao KA, Green MR, Crooks P, Jain S, Tobin J, Steptoe RJ, Gandhi MK. The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma. Clin Cancer Res 23(7):1820-1828, 2017. e-Pub 2017. PMID: 27649554.
61. Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, Czerwinski DK, Carlton VE, Moorhead M, Faham M, Kohrt HE, Carette J, Green MR, Davis MM, Levy R, Elias JE, Alizadeh AA. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature 543(7647):723-727, 2017. e-Pub 2017. PMID: 28329770.
62. Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood 129(6):759-770, 2017. e-Pub 2017. PMID: 28011673.
63. Bouska A, Bi C, Lone W, Zhang W, Kedwaii A, Heavican T, Lachel CM, Yu J, Ferro R, Eldorghamy N, Greiner TC, Vose J, Weisenburger DD, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, Siebert R, Miles RR, Dave S, Reddy A, Delabie J, Staudt LM, Song JY, McKeithan TW, Fu K, Green M, Chan WC, Iqbal J. Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets. Blood, 2017. e-Pub 2017. PMID: 28801451.
64. Rogozin IB, Lada AG, Goncearenco A, Green MR, De S, Nudelman G, Panchenko AR, Koonin EV, Pavlov YI. Activation induced deaminase mutational signature overlaps with CpG methylation sites in follicular lymphoma and other cancers. Sci Rep 6:38133, 2016. e-Pub 2016. PMID: 27924834.
65. Keane C, Vari F, Hertzberg M, Cao KA, Green MR, Han E, Seymour JF, Hicks RJ, Gill D, Crooks P, Gould C, Jones K, Griffiths LR, Talaulikar D, Jain S, Tobin J, Gandhi MK. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematol 2(10):e445-55, 2015. e-Pub 2015. PMID: 26686046.
66. Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, Takahashi K, Glover C, Keane C, Kihira S, Visser B, Callahan J, Kong KA, Faham M, Corbelli KS, Miklos D, Advani RH, Levy R, Hicks RJ, Hertzberg M, Ohgami RS, Gandhi MK, Diehn M, Alizadeh AA. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125(24):3679-87, 2015. e-Pub 2015. PMID: 25887775.
67. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12(5):453-7, 2015. e-Pub 2015. PMID: 25822800.
68. Green MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, Irish J, Stehr H, Vicente-Dueñas C, Romero-Camarero I, Sanchez-Garcia I, Plevritis SK, Arber DA, Batzoglou S, Levy R, Alizadeh AA. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A 112(10):E1116-25, 2015. e-Pub 2015. PMID: 25713363.
69. Green MR, Vicente-Dueñas C, Romero-Camarero I, Long Liu C, Dai B, González-Herrero I, García-Ramírez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, Jiménez R, Martínez-Climent JA, Criado FJ, Cenador MB, Zhao S, Natkunam Y, Lossos IS, Majeti R, Melnick A, Cobaleda C, Alizadeh AA, Sánchez-García I. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nat Commun 5:3904, 2014. e-Pub 2014. PMID: 24887457.
70. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 123(6):2447-63, 2013. e-Pub 2013. PMID: 23728179.
71. Aya-Bonilla C, Green MR, Camilleri E, Benton M, Keane C, Marlton P, Lea R, Gandhi MK, Griffiths LR. High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to Non-Hodgkin's lymphoma. Genes Chromosomes Cancer 52(5):467-79, 2013. e-Pub 2013. PMID: 23341091.
72. Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, Kela I, Hopmans ES, Myklebust JH, Ji H, Plevritis SK, Levy R, Alizadeh AA. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121(9):1604-11, 2013. e-Pub 2013. PMID: 23297126.
73. Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 121(8):1367-76, 2013. e-Pub 2013. PMID: 23297127.
74. Romero-Camarero I, Jiang X, Natkunam Y, Lu X, Vicente-Dueñas C, Gonzalez-Herrero I, Flores T, Garcia JL, McNamara G, Kunder C, Zhao S, Segura V, Fontan L, Martínez-Climent JA, García-Criado FJ, Theis JD, Dogan A, Campos-Sánchez E, Green MR, Alizadeh AA, Cobaleda C, Sánchez-García I, Lossos IS. Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nat Commun 4:1338, 2013. e-Pub 2013. PMID: 23299888.
75. Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, Polak K, Tondera D, Gounarides J, Yin H, Zhou F, Green MR, Chen L, Monti S, Marto JA, Shipp MA, Danial NN. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 22(4):547-60, 2012. e-Pub 2012. PMID: 23079663.
76. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18(6):1611-8, 2012. e-Pub 2012. PMID: 22271878.
77. Green MR, Camilleri E, Gandhi MK, Peake J, Griffiths LR. A novel immunodeficiency disorder characterized by genetic amplification of interleukin 25. Genes Immun 12(8):663-6, 2011. e-Pub 2011. PMID: 21776014.
78. Kondratiev S, Duraisamy S, Unitt CL, Green MR, Pinkus GS, Shipp MA, Kutok JL, Drapkin RI, Rodig SJ. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. Am J Surg Pathol 35(10):1531-9, 2011. e-Pub 2011. PMID: 21921781.
79. Green MR, Aya-Bonilla C, Gandhi MK, Lea RA, Wellwood J, Wood P, Marlton P, Griffiths LR. Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. Genes Chromosomes Cancer 50(5):313-26, 2011. e-Pub 2011. PMID: 21305641.
80. Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, Currie T, Armant M, Takeyama K, Monti S, Rabinovich GA, Ritz J, Kutok JL, Shipp MA. Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood 117(16):4315-22, 2011. e-Pub 2011. PMID: 21300977.
81. Green MR, Monti S, Dalla-Favera R, Pasqualucci L, Walsh NC, Schmidt-Supprian M, Kutok JL, Rodig SJ, Neuberg DS, Rajewsky K, Golub TR, Alt FW, Shipp MA, Manis JP. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. Proc Natl Acad Sci U S A 108(7):2873-8, 2011. e-Pub 2011. PMID: 21282644.
82. Nguyen-Van D, Keane C, Han E, Jones K, Nourse JP, Vari F, Ross N, Crooks P, Ramuz O, Green M, Griffith L, Trappe R, Grigg A, Mollee P, Gandhi MK. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. Am J Blood Res 1(2):146-59, 2011. e-Pub 2011. PMID: 22432076.
83. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268-77, 2010. e-Pub 2010. PMID: 20628145.
84. Green MR, Jardine P, Wood P, Wellwood J, Lea RA, Marlton P, Griffiths LR. A new method to detect loss of heterozygosity using cohort heterozygosity comparisons. BMC Cancer 10:195, 2010. e-Pub 2010. PMID: 20462409.
85. Green MR, Gandhi MK, Courtney MJ, Marlton P, Griffiths L. Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NFkappaB activity in Follicular Lymphoma. Leuk Res 33(12):1699-702, 2009. e-Pub 2009. PMID: 19487025.
86. Green M, Gandhi MK, Camilleri E, Marlton P, Lea R, Griffiths L. High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkin's lymphoma. Leuk Res 33(5):731-4, 2009. e-Pub 2009. PMID: 18929412.

Invited Articles

1. Green MR. The Role of Exhaustion in CAR T-cell therapy. Cancer Cell 39(7):885-888, 2021. e-Pub 2021. PMID: 34256903.
2. Green M, Vicente-Duenas C, Alizadeh A, Sanches Garcia I. Hit-and-run tumor stem cell reprogramming by the Bcl6 oncogene. Cell Cycle 13:1831-1832, 2014. e-Pub 2014. PMID: 24867153.
3. Green M, Alizadeh A. Common progenitor cells (CPCs) in mature B-cell malignancies: Implications for therapy. Curr Opin Hematol 21:333-340, 2014. e-Pub 2014. PMID: 24811163.

Review Articles

1. Yang J, Chen Y, Jing Y, Green MR, Han L. Advancing CAR T cell therapy through the use of multidimensional omics data. Nat Rev Clin Oncol 20(4):211-228, 2023. e-Pub 2023. PMID: 36721024.
2. Yang H, Green MR. Harnessing lymphoma epigenetics to improve therapies. Blood 136(21):2386-2391, 2020. e-Pub 2020. PMID: 33206943.
3. Green M. Chromatin modifying genes in follicular lymphoma. Blood 131(6):595-604, 2018. e-Pub 2018. PMID: 29158360.
4. Lunning M, Green M. Mutation of chromatin modifiers and organizers; an emerging hallmark of B-cell lymphoma. Blood Cancer J 5:e361, 2015. e-Pub 2015. PMID: 26473533.

Other Articles

1. Akkad N, Feng L, Westin J, Hagemeister F, Lee H, Fayad L, Ahmed S, Nair R, Rodriguez A, Strati P, Chihara D, Flowers C, Claret L, Ibanez K, Wang M, Fowler N, Henderson J, Davis R, Neelapu S, Green M, Nastoupil L A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma. Blood Advances, 2025. PMID: 40517417.
2. Dai Y, Kizhakeyil A, Chihara D, Li X, Liu Y, Zuniga T, Wilson A, Henderson J, Vibe D, Petrosyants A, Jacobson C, Sarachakov A, Nomie K, Kryukov K, Bagaev A, Chauhan A, Westin J, Flowers C, Vega F, L W, Green M Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B-cell lymphoma. Nature Genetics.
3. Green MR, Sarott R, Gourisankar S,, Karim B, Nettles S, Yang H, Dwyer B, Simanauskaite J,, Tse J, Abuzaid H, Krokhotin A, Zhang T, Hinshaw S, Crabtree G, Gray N Borrowing transcriptional kinases to activate apoptosis. Science 386, 2024. PMID: 39361741.

Editorials

1. Tobin JWD, Green MR, Gandhi MK. The PO4-tential for Less Toxic CAR T-cell Therapies. Cancer Immunol Res 10(12):1422, 2022. PMID: 36327248.
2. Strati P, Green MR. A ticking clock for B-cell tumors. Nature Cancer 1(11):1035-1037, 2020. PMID: 35122068.
3. Green MR, Neelapu SS. Not So FASt: Tumor Cells Resisting Death Drive CAR T-cell Dysfunction. Cancer Discov 10(4):492-494, 2020. PMID: 32238396.
4. Green M. Considering Clonality in Precision Medicine. ASCO Post 6(11), 2015.

Abstracts

1. Li X, Singhal K, Deng Q, Chihara D, Russler-Germain D, Hussein U, Foltz J, Henderson J, Wilson A, Schmidt E, Nizamuddin I, Dinh T, Sun R, Vega F, Flowers C, Griffith O, Fehniger T, Griffith M, Green M. Comprehensive characterization of the non-tumor microenvironment of relapsed/refractory large B-cell lymphoma identifies patients with greatest benefit from CD19 CAR T-cell therapy [Oral]. AACR Advances in Malignant Lymphoma, 2024. e-Pub 2024.
2. Lee HC, Li J, Lin H, Murga AD, Rodriguez GM, Mohamed ME, Henderson J, Rodriguez S, Becnel MR, Weber DM, Iyer SP, Kaufman GP, Thomas SK, Manasanch EE, Patel KK, Noga SJ, Green MR, Orlowski RZ, Haymaker CL. Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed by an In-Class Proteasome Inhibitor Transition to Daratumumab, Ixazomib, and Dexamethasone in Relapsed Refractory Multiple Myeloma. Annual Meeting of the American Society of Hematology, 2023. e-Pub 2023.
3. Wang B, Reville PK, Jelloul FZ, Desai PN, Borges P, Ly C, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Vaugh N, Baran N, Deng Q, Matthews J, Gunaratne P, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver N, Green MR, Konopleva MY, Futreal A, Post SM, Abbas HA. IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies. Annual Meeting of the American Society of Hematology, 2023. e-Pub 2023.
4. Sheikh I, Choi A, Reville P, Henderson J, Rojas E, Le C, Okwuchi C, Carrio R, Pate N, Malley K, Bangari D, Givigan J, Shi C, Liu B, Byers T, Sassoon I, Cucchetti M, Wang R, Agarwal M, Abbadessa G, Meng R, Meibalan E, Powers L, Cao J, Ying X, Balko K, Yu Q, Jiao J, Cortez-Retamozo V, Sidhu S, Shaffer D, Li X, Green M. SAR444245, a non-alpha IL2, rescues chronic antigen- and CAR-driven T-cell dysfunction [Oral]. European Hematology Association Annual Meeting, 2023. e-Pub 2023.
5. Cherng HJ, Alig S, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister FB, Rodriguez MA, Lee HJ, McDonnell T, Flowers C, Vega F, Green MR, Alizadeh AA, Davis RE, Westin J. Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma. ASCO Annual Meeting, 2022. e-Pub 2022.
6. Yang H, Zhang W, Ravanmehr V, Henderson J, Deng Q, Samaniego F, Rodrigues-Lima F, Green M. Crebbp KAT domain missense mutations alter its dynamic loading onto chromatin and create a transcription factor sink. Annual Meeting of the American Society of Hematology, 2022. e-Pub 2022.
7. Kizhakeyil A, Ghosh S, Rojas-Neira E, Deng Q, Henderson J, Showell J, Melnick A, Beguelin W, Vega F, Nastoupil LJ, Green MR. DTX1 controls germinal center B-cell development and lymphomagenesis [Oral]. Annual Meeting of the American Society of Hematology, 2022. e-Pub 2022.
8. Steiner RE, Strati P, Flowers C, Neelapu SS, Green MR, Nastoupil LJ, Hagemeister FB, Feng L, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Westin J. Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma. ASCO Annual Meeting, 2022. e-Pub 2022.
9. Deng Q, Meydan C, Lakra P, Barisic D, Chin CR, Rojas-Neira E, Ravanmehr V, Henderson J, Gou P, El-Mallawany NK, Allen C, Cuglievan B, Vega F, Mason CE, Melnick A, Green MR. Smarca4 (Brg1) controls germinal center B-cell development and is a haploinsufficient tumor suppressor in lymphoma [Oral]. Annual Meeting of the American Society of Hematology, 2022. e-Pub 2022.
10. Strati P, Li X, Deng Q, Feng L, Sun R, Jallouk A, Adkins S, Cain T, Johncy S, Steiner R, Ahmed S, Chihara D, Fayad L, Iyer S, Horowitz S, Nehlsen R, Nastoupil L, Nair R, Hassan A, Daoud T, Hawkins M, Samaniego F, Rodriguez M, Shpall E, Kebriaei P, Flowers C, Hong D, Westin J, Neelapu S, Green M. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-cell Lymphoma. Annual Meeting of the American Society of Hematology, 2022. e-Pub 2022.
11. Westin JR, Steiner R, Feng L, Strati P, Flowers CR, Neelapu SS, Nastoupil L, Chihara D, Hagemeister FB, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Davis E, Green MR. Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL. Annual Meeting of the American Society of Hematology 138(Suppl 1), 2021. e-Pub 2021.
12. Gouni S, Westin JR, Mistry H, Steiner RE, James J, Parmar, S, Noorani M, Fowler NH, Horowitz SB, Feng L, Fayad LE, Iyer SP, Green MR, Hawkins M Flowers CR, Ahmed S, Nastoupil L, Neelapu SS, Nieto Y, Strati P. Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion. Annual Meeting of the American Society of Hematology 138(Suppl 1), 2021. e-Pub 2021.
13. Steiner R, Strati P, Flowers C, Neelapu S, Green M, Nastoupil L, Hagemeister F, Feng L, Ahmed S, Nair R, Fayad L, Lee H, Rodriguez M, Westin J. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. Annual Meeting of the American Society of Hematology, 2021. e-Pub 2021.
14. Nair R, Deen N, Ahmed S, Miranda RN, Fowler NH, Fayad L, Steiner RE, Hagemeister FB, Rodriguez MA, Lee HJ, Strati P, Malpica-Castillo L, Chihara D, Jain P, Gunther JR, Flowers CR, Medeiros L, Nieto Y, Ramdial JL, Neelapu SS, Nastoupil L, Green MR, Wang M, Vega F, Feng L, Iyer SP, Westin JR. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. Annual Meeting of the American Society of Hematology, 2021. e-Pub 2021.
15. Steiner RE, Strati P, Flowers CR, Neelapu SS, Green MR, Nastoupil L, Hagemeister FB, Feng L, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Westin JR. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. Annual Meeting of the American Society of Hematology 138(Suppl 1), 2021. e-Pub 2021.
16. Jain N, Ferrajoli A, Thompson PA, Konopleva M, Green MR, Sampath D, Neelapu SS, Takahashi K, Strati P, Burger JA, Kanagal-Shamanna R, Khoury JD, Garg N, Su X, Wang X, Patel H, Ayala A, Kantarjian H, Keating MJ, Wierda WG. Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation. Annual Meeting of the American Society of Hematology 138(Suppl 1), 2021. e-Pub 2021.
17. Nair R, Deen N, Ahmed S, Miranda RN, Fowler NH, Fayad L, Steiner RE, Hagemeister FB, Rodriguez MA, Lee HJ, Strati P, Malpica-Castillo L, Chihara D, Jain P, Gunther JR, Flowers CR, Medeiros LJ, Nieto Y, Ramdial JL, Neelapu SS, Nastoupil L, Green MR, Wang M, Vega F, Feng L, Iyer SP, Westin JR. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. Annual Meeting of the American Society of Hematology 138(Suppl 1), 2021. e-Pub 2021.
18. Gouni S, Westin J, Mistry H, Steiner R, James J, Parmar S, Noorani M, Fowler N, Horowitz S, Feng L, Fayad L, Iyer S, Green M, Hawkins M, Flowers C, Ahmed S, Nastoupil L, Neelapu S, Nieto Y, Strati P. Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion. Annual Meeting of the American Society of Hematology, 2021. e-Pub 2021.
19. H-JJ C, Sun R, Yang H, Deng Q, Fayad L, Fowler NH, Parmar S, Ahmed S, Steiner RE, Hagemeister FB, Lee HJ, Nair R, Rodriguez MA, Samaniego F, Iyer SP, Nastoupil L, Neelapu SS, Strati P, Westin JR, Green MR. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. Annual Meeting of the American Society of Hematology 138(Suppl 1), 2021. e-Pub 2021.
20. Szydlowski M, Garbicz F, Jabłońska E, Górniak P, Pyrzynska B, Bojarczuk K, Komar D, Prochorec-Sobieszek M, Szumera-Ciećkiewicz A, Rymkiewicz G, Cybulska M, Statkiewicz M, Gajewska M, Mikula M, Golas A, Domagała J, Winiarska M, Graczyk-Jarzynka A, Bialopiotrowicz E, Polak A, Barankiewicz J, Pula B, Green M, Nowis D, Golab J, Tomirotti A, Brzózka K, Pacheco-Blanco M, Kupcova K, Havranek O, Chapuy B, Juszczynski P. Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies. Annual Meeting of the American Society of Hematology, 2020. e-Pub 2020.
21. Abbas H, Hao D, Tomczak K, Barrodia P, Im J, Reville P, Alaniz Z, Wang W, Wang R, Wang F, Takahashi K, Ning J, Ding M, Matthews J, Little L, Zhang J, Basu S, DiNardo C, Kadia T, Ravandi F, Borthakur G, Konopleva M, Garcia-Manero G, Green M, Alatrash G, Sharma P, Allison J, Kornblau S, Rai K, Wang L, Futreal A, Daver N. Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy. Annual Meeting of the American Society of Hematology, 2020. e-Pub 2020.
22. Fiskus W, Mill C, Lara B, Birdwell C, Green M, Khoury J, Bhalla K. BET Protein Antagonist-Based Therapy of Novel Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL). Annual Meeting of the American Society of Hematology, 2020. e-Pub 2020.
23. Saini N, Chang C, Strati P, Nastoupil L, Westin J, Nair R, Fayad L, Ahmed S, Lee H, Iyer S, Steiner R, Greenbaum U, Kebriaei P, Shpall E, Jain N, Green M, Ajami N, Flowers C, Champlin R, Wargo J, Neelapu S, Jenq R. Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. Annual Meeting of the American Society of Hematology, 2020. e-Pub 2020.
24. Westin J, Nastoupil L, Fayad L, Hagenmeister F, Oki Y, Turturro F, Ahmed S, Rodriguez M, Lee H, Steiner R, Nair R, Parmar S, Young K, McDonnell T, Chuang H, Green M, Neelapu S, Davis R. Smart Start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. ASCO Annual Meeting, 2019. e-Pub 2019.
25. Nastoupil L, Westin J, Hagemeister F, Lee H, Fayad L, Samaniego F, Ahmed S, Claret L, Steiner R, Nair R, Parmar S, Rodriguez M, Wang M, Green M, Davis R, Neelapu S, Fowler N. Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL). Annual Meeting of the American Society of Hematology, 2019. e-Pub 2019.
26. Westin J, Nastoupil L, Fayad L, Hagemeister F, Oki Y, Turturro F, Ahmed S, Rodrigues M, Lee H, Steiner R, Nair R, Parmar S, Young K, McDonnell T, Chuang H, Green M, Neelapu S, Davis E. Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results. Annual Meeting of the American Society of Hematology, 2019. e-Pub 2019.
27. Nastoupil L, Lee H, Hagemeister F, Westin J, Samaniego F, Feng L, John J, Forbes S, Fayad L, Green M, Davis E, Neelapu S, Fowler N. Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study. Annual Meeting of the American Society of Hematology, 2018. e-Pub 2018.
28. Green M, Brattman S, Liu C, Takahashi K, Glover C, Keane C, Kihira S, Kong K, Faham M, Corbelli K, Miklos D, Advani R, Levy R, Hertzberg M, Gandhi M, Diehn M, Alizadeh A. Utility of non-invasive monitoring of circulating tumor DNA at diagnosis, interim therapy, and relapse of DLBCL using high-throughput sequencing of immunoglobulin genes. Annual Meeting of the American Society of Hematology, 2013. e-Pub 2013.
29. Green M, Gentles A, Nair R, Irish J, Kihira S, Liu C, Kela I, Hoppmans E, Myklebust J, Ji H, Plevritis S, Levy R, Alizadeh A. The structure of stepwise clonal evolution events shaping Follicular lymphoma coding genomes [Oral]. International Congress on Malignant Lymphoma, 2013. e-Pub 2013.
30. Green M, Gentles A, Nair R, Irish J, Levy R, Alizadeh A. Hierarchy of somatic mutations arising during genomic evolution and progression of Follicular lymphoma [Oral]. Annual Meeting of the American Society of Hematology, 2012. e-Pub 2012.

Book Chapters

1. Deng, Q, Green, M. The role of epigenetic dysregulation in lymphoma biology, 199-208, 2023.
2. Tadros S, Green MR. Genomic Drivers of Follicular Lymphoma. In: Follicular Lymphoma: Current Management and Novel Approaches.